Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
84
Recruiting, industry sponsors, Infectious disease and vaccines, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,780
84 trials
Showing 1 to 25, recently updated first.
- A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIVPivotal-lookingRecruiting
BioNTech SEIndustry
NCT07698600 · 126 participants (planned) · Start Aug 4, 2026 · Primary completion Feb 2028
Drug: BNT168 · For: HIV -1 Infection
Sites: St Louis, Missouri; Knoxville, Tennessee; Houston, Texas · 6 sites in all
Sinomune Pharmaceutical Co., LtdIndustry
NCT07668999 · 64 participants (planned) · Start Mar 31, 2027 · Primary completion Mar 31, 2027
Drug: ZYG24004 1% topical film-forming formulation; ZYG24004 3% topical film-forming formulation and 1 more · For: Tinea Pedis
Sites: Beijing, China
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT07944482 · 24 participants (planned) · Start Jul 3, 2026 · Primary completion Dec 31, 2026
Drug: GST-HG141 · For: Chronic Hepatitis b
Sites: Suzhou, China
- Safety and Efficacy of SUM-191 for Patients With Bacterial ConjunctivitisPivotal-lookingRecruiting
Senju USA, Inc.Industry
NCT07565103 · 426 participants (planned) · Start Jun 25, 2026 · Primary completion Aug 15, 2028
Drug: SUM-191; Placebo · For: Bacterial Conjunctivitis
Sites: Delray Beach, Florida; Austin, Texas
- A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)Pivotal-lookingRecruiting
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT07300085 · 710 participants (planned) · Start Nov 8, 2025 · Primary completion Dec 31, 2026
Drug: Fluzone® High-Dose (HD) influenza vaccine · For: Healthy Participants
Sites: Phoenix, Arizona; Glendale, California; Miami, Florida · 15 sites in all
PT Bio FarmaIndustry
NCT07647107 · 60 participants (planned) · Start Sep 8, 2026 · Primary completion Jul 2027
Drug: LipovaxinS4-EAH (Middle Dose); LipovaksinS4-EAH (High Dose) and 1 more · For: Tuberculosis; TB Infection
Sites: Jakarta Pusat, Indonesia
- Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)Pivotal-lookingRecruiting
Serum Institute of India Pvt. Ltd.Industry
NCT07855172 · 186 participants (planned) · Start Nov 1, 2026 · Primary completion Oct 2027
Drug: Hexavalent (DTwP-HepB-rPV-Hib) Vaccine; HEXASIIL · For: Diptheria Immunization; Tetanus Immunization; Pertussis Immunization and 3 more
Sites: Dhaka, Bangladesh
- A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07855276 · 30 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 29, 2027
Drug: LOU064; Placebo · For: Hidradenitis Suppurativa
Sites: San Diego, California; Mayfield Heights, Ohio
Loki Therapeutics, Inc.Industry
NCT07828236 · 18 participants (planned) · Start Oct 15, 2026 · Primary completion Oct 15, 2028
Drug: Lm-LLO-TT · For: Pancreas Cancer, Duct Cell Adenocarcinoma; Pancreatic Cancer; Advanced Pancreatic Adenocarcinoma
Sites: The Bronx, New York
- First Time in Human Study of Long Acting VH4524184 FormulationsPivotal-lookingRecruiting
ViiV HealthcareGSK (GSK)
NCT06310551 · 348 participants (planned) · Start Mar 21, 2024 · Primary completion May 28, 2029
Drug: Oral VH4524184; VH4524184 Formulation A SC and 8 more · For: HIV Infections
Sites: Lenexa, Kansas; Las Vegas, Nevada; Austin, Texas · 5 sites in all
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07870330 · 96 participants (planned) · Start Oct 7, 2026 · Primary completion Dec 7, 2027
Drug: mRNA-1010; Fluarix Trivalent · For: Seasonal Influenza
Sites: Modesto, California; Aurora, Colorado; Minneapolis, Minnesota · 6 sites in all
ViiV HealthcareGSK (GSK)
NCT05418868 · 214 participants (planned) · Start Jun 14, 2022 · Primary completion Mar 31, 2028
Drug: Cabotegravir 200 mg/mL; CAB >=400 mg/mL and 4 more · For: HIV Infections
Sites: Orlando, Florida; Las Vegas, Nevada; Austin, Texas
SanofiSanofi (SNY)
NCT06891417 · 80 participants (planned) · Start Mar 27, 2025 · Primary completion Nov 3, 2027
Drug: Chlamydia mRNA Vaccine · For: Chlamydia Trachomatis Immunization
Sites: Bruce, Australia; Maroubra, Australia; Sydney, Australia · 7 sites in all
- A Study of BLB-201 RSV Vaccine in Infants and ChildrenPivotal-lookingRecruiting
Blue Lake Biotechnology Inc.Industry
NCT05655182 · 137 participants (planned) · Start Mar 9, 2023 · Primary completion Dec 30, 2028
Drug: PIV5-vectored RSV Vaccine (BLB-201) Low Dose; PIV5-vectored RSV Vaccine (BLB-201) High Dose and 1 more · For: Respiratory Syncytial Virus Infections
Sites: La Mesa, California; Modesto, California; San Diego, California · 18 sites in all
- A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult ParticipantsPivotal-lookingRecruiting
ViiV HealthcareGSK (GSK)
NCT07818915 · 112 participants (planned) · Start Sep 15, 2026 · Primary completion Dec 26, 2028
Drug: VH4367310; Placebo · For: HIV Infections
Sites: Glendale, California; Baltimore, Maryland
- Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult ParticipantsPivotal-lookingRecruiting
ShionogiIndustry
NCT07093580 · 128 participants (planned) · Start Jul 29, 2025 · Primary completion Jun 30, 2028
Drug: S-892216-LAI; Placebo · For: Healthy Participants
Sites: Cypress, California; Lenexa, Kansas; Salt Lake City, Utah
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07663838 · 42 participants (planned) · Start Aug 15, 2026 · Primary completion Jan 5, 2027
Drug: GenSci142 capsule; clindamycin phosphate vaginal cream · For: Randomized; Open-label; Safety and 3 more
Sites: Beijing, China; Xinxiang, China; Nanjing, China · 9 sites in all
Corvus Pharmaceuticals, Inc.Industry
NCT07828860 · 25 participants (planned) · Start Sep 17, 2026 · Primary completion Dec 2027
Drug: Soquelitinib · For: Hidradenitis Suppurativa (HS)
Sites: West Lafayette, Indiana; Bowling Green, Kentucky; Owensboro, Kentucky · 11 sites in all
- Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07734649 · 2,400 participants (planned) · Start Jul 22, 2026 · Primary completion May 3, 2028
Drug: RSV+HMPV vaccine; Control Vaccine 3 and 3 more · For: Respiratory Syncytial Virus Immunization; Human Metapneumovirus Immunization; Healthy Volunteers
Sites: Gadsden, Alabama; Vestavia Hills, Alabama; Huntington Beach, California · 50 sites in all
Incyte CorporationIncyte (INCY)
NCT07049575 · 24 participants (planned) · Start Nov 3, 2025 · Primary completion Dec 9, 2026
Drug: Ruxolitinib Cream · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Fountain Valley, California; Northridge, California · 21 sites in all
SNIPR Biome Aps.Industry
NCT06938867 · 66 participants (planned) · Start Dec 4, 2024 · Primary completion Oct 2027
Drug: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli · For: E Coli Infections; Allogenic Transplant Patients
Sites: Duarte, California; San Francisco, California; Baltimore, Maryland · 10 sites in all
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruiting
SciTech Development, Inc.Industry
NCT04234048 · 46 participants (planned) · Start Dec 18, 2023 · Primary completion Jun 1, 2028
Drug: Fenretinide · For: T-cell Lymphoma; Cutaneous/Peripheral T-Cell Lymphoma; Peripheral T-cell Lymphoma and 8 more
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 10 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07784894 · 28 participants (planned) · Start Aug 20, 2026 · Primary completion Nov 17, 2026
Drug: Ganfeborole; Microgynon · For: Tuberculosis
Sites: Madrid, Spain
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07300267 · 210 participants (planned) · Start Jan 13, 2026 · Primary completion Oct 24, 2028
Drug: V118C (Stage 1); V118C (Stage 2) and 2 more · For: Pneumococcal Infection
Sites: Madera, California; Miami, Florida; Tampa, Florida · 15 sites in all
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)Recruiting
Estrella Immunopharma, Inc.Industry
NCT06343311 · 27 participants (planned) · Start Jun 1, 2024 · Primary completion Jul 31, 2027
Drug: EB103 · For: B-Cell Non-Hodgkin's Lymphoma (NHL); Lymphoma, Non-Hodgkins; Lymphomas Non-Hodgkin's B-Cell and 12 more
Sites: Sacramento, California; Cleveland, Ohio; Portland, Oregon · 5 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.